Skip to content

Glucosamine Hydrochloride combined with Hyaluronate Sodium for Temporomandibular Joint Disorders: a Randomized Controlled Trial

Glucosamine Hydrochloride combined with Hyaluronate Sodium for Temporomandibular Joint Disorders: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000592
Enrollment
Unknown
Registered
2009-11-23
Start date
2009-12-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

temporomandibular joint disorders(osteoarthritis type)

Interventions

Group A:Intra-articular injection of sodium hyaluronate into the upper and lower camber of TMJ, once every week, for four weeks. Taking glucosamine hydrochloride (240mg), two pills each time, three ti
Group B:Intra-articular injection of sodium hyaluronate into the upper and lower camber of TMJ, once every week, for four weeks. Taking placebo (no active component), two pills each time, three times

Sponsors

West China Hospital of Stomatology, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Males or females of 16~70 years old; 2. Be diagnosted as temporomandibular disorders (osteoarthritis type) both clinically and radiographically; 3. The participants who consent to participant in.

Exclusion criteria

Exclusion criteria: 1. No sign of osteoarthritis of the temporomandibular joint, or with the muscular disorders of TMJ; 2. Allergic to serval drugs or have some allergic diseases; 3. Get other treatment for the disease or take similar drugs within 4 weeks; 4. Participanted in other clinical trials within 3 months; 5. With psychological diseases or could not cooperate; 6. Have severe diseases of the heart, liver, kidney and blood system or have infection in the temporomandibular joint area.

Design outcomes

Primary

MeasureTime frame
clinical sign;synthesised variables;concentration of IL-6 in the articular fluid;cone beam CT variables;participants assessed variable;

Secondary

MeasureTime frame
economic evaluation variables;quality of life;

Countries

China

Contacts

Public ContactZongdao Shi, Chunjie Li
shizd0664@163.com+86 028 6153097

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026